• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Doximity Announces Fiscal 2024 Second Quarter Financial Results

    11/9/23 4:01:00 PM ET
    $DOCS
    EDP Services
    Technology
    Get the next $DOCS alert in real time by email

    Total revenues of $113.6 million, up 11% year-over-year

    Net income margin of 27% and adjusted EBITDA margin of 48%

    Net income growth of 16% and adjusted EBITDA growth of 18% year-over-year

    Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2024 second quarter ended September 30, 2023.

    "We're proud to make medicine mobile, with another quarter of record engagement across our entire platform," said Jeff Tangney, co-founder and CEO of Doximity. "Over 550,000 unique providers used our generative AI, telehealth, messaging, and scheduling workflow tools in Q2 to provide better care for their patients."

    Fiscal 2024 Second Quarter Financial Highlights

    All comparisons, unless otherwise noted, are to the three months ended September 30, 2022.

    • Revenue: Revenue of $113.6 million, versus $102.2 million, an increase of 11% year-over-year.
    • Net income and non-GAAP net income: Net income of $30.6 million, versus $26.3 million, representing a margin of 26.9%, versus 25.7%. Included in net income was restructuring expense of $7.9 million, which consisted primarily of severance, benefits and stock-based compensation for equity award modification for terminated employees. Non-GAAP net income of $45.6 million, versus $36.2 million, representing a margin of 40.1%, versus 35.4%.
    • Adjusted EBITDA: Adjusted EBITDA of $54.2 million, versus $46.0 million, an increase of 18% year-over-year, representing adjusted EBITDA margins of 47.7%, versus 45.0%.
    • Diluted net income per share and non-GAAP diluted net income per share: Diluted net income per share was $0.15, versus $0.12, while non-GAAP diluted net income per share was $0.22, versus $0.17.
    • Operating cash flow and free cash flow: Operating cash flow of $12.9 million, versus $39.5 million, a decrease of 67% year-over-year, and free cash flow of $11.6 million, versus $37.7 million, a decrease of 69% year-over-year.

    Financial Outlook

    Doximity is providing guidance for its fiscal third quarter ending December 31, 2023 as follows:

    • Revenue between $127 million and $128 million.
    • Adjusted EBITDA between $61 million and $62 million.

    Doximity is updating guidance for its fiscal year ending March 31, 2024 as follows:

    • Revenue between $460 million and $472 million.
    • Adjusted EBITDA between $207 million and $219 million.

    Stock Repurchase Program

    Doximity's board of directors authorized another program to repurchase up to $70 million of the Company's Class A common stock. The repurchases are expected to be executed from time to time over the next 12 months, subject to general business and market conditions and other investment opportunities, through open market purchases or privately negotiated transactions, including through Rule 10b5-1 plans. All prior repurchase programs were completed as of October 2023.

    Conference Call Information

    Doximity will host a webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com. The archived webcast will be available on the Company's Investor Relations page shortly after the call.

    About Doximity

    Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The Company's network members include over 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, and conduct virtual patient visits. Doximity's mission is to help doctors be more productive so they can provide better care for their patients. For more information, visit www.doximity.com.

    Forward-Looking Statements

    Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors including (i) the timing and scope of anticipated stock repurchases; (ii) the impact of uncertainty in the current economic environment and macroeconomic uncertainty; (iii) our ability to retain existing members or add new members to our platform and maintain or grow their engagement with our platform; (iv) our ability to attract new customers or retain existing customers; (v) the impact of our prioritization of our members' interests; (vi) breaches in our security measures or unauthorized access to members' data; (vii) our ability to maintain or manage our growth, and other risks and factors that are beyond our control including, without limitation, those set forth in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023 and as may be updated in any subsequent Quarterly Reports on Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could cause actual results to differ materially from those contained in our forward-looking statements. The forward-looking statements made in this press release relate only to management's beliefs and assumptions as of this date. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    DOXIMITY, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands)

    (unaudited)

     

     

    September 30, 2023

    March 31, 2023

    Assets

     

     

    Current assets:

     

     

    Cash and cash equivalents

    $

    108,403

     

    $

    158,027

     

    Marketable securities

     

    621,451

     

     

    682,972

     

    Accounts receivable, net

     

    97,217

     

     

    107,047

     

    Prepaid expenses and other current assets

     

    32,789

     

     

    22,289

     

    Deferred contract costs, current

     

    2,960

     

     

    5,118

     

    Total current assets

     

    862,820

     

     

    975,453

     

    Property and equipment, net

     

    11,780

     

     

    11,279

     

    Deferred income tax assets

     

    39,289

     

     

    34,907

     

    Operating lease right-of-use assets

     

    12,743

     

     

    13,819

     

    Intangible assets, net

     

    29,440

     

     

    31,836

     

    Goodwill

     

    67,940

     

     

    67,940

     

    Other assets

     

    1,559

     

     

    1,654

     

    Total assets

    $

    1,025,571

     

    $

    1,136,888

     

    Liabilities and Stockholders' Equity

     

     

    Current liabilities:

     

     

    Accounts payable

    $

    714

     

    $

    1,272

     

    Accrued expenses and other current liabilities

     

    29,086

     

     

    31,245

     

    Deferred revenue, current

     

    91,446

     

     

    105,238

     

    Operating lease liabilities, current

     

    1,935

     

     

    1,752

     

    Total current liabilities

     

    123,181

     

     

    139,507

     

    Deferred revenue, non-current

     

    237

     

     

    198

     

    Operating lease liabilities, non-current

     

    13,119

     

     

    13,885

     

    Contingent earn-out consideration liability, non-current

     

    10,448

     

     

    15,942

     

    Other liabilities, non-current

     

    7,119

     

     

    1,240

     

    Total liabilities

     

    154,104

     

     

    170,772

     

    Stockholders' Equity

     

     

    Preferred stock

     

    —

     

     

    —

     

    Common stock

     

    188

     

     

    194

     

    Additional paid-in capital

     

    794,804

     

     

    762,150

     

    Accumulated other comprehensive loss

     

    (8,928

    )

     

    (14,083

    )

    Retained earnings

     

    85,403

     

     

    217,855

     

    Total stockholders' equity

     

    871,467

     

     

    966,116

     

    Total liabilities and stockholders' equity

    $

    1,025,571

     

    $

    1,136,888

     

    DOXIMITY, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except per share data)

    (unaudited)

     

     

    Three Months Ended

    September 30,

    Six Months Ended

    September 30,

     

    2023

    2022

    2023

    2022

    Revenue

    $

    113,612

    $

    102,185

    $

    222,081

    $

    192,824

    Cost of revenue(1)

     

    12,759

     

    13,210

     

    25,912

     

    26,287

    Gross profit

     

    100,853

     

    88,975

     

    196,169

     

    166,537

    Operating expenses(1):

     

     

     

     

    Research and development

     

    19,958

     

    19,104

     

    41,889

     

    38,126

    Sales and marketing

     

    30,201

     

    29,021

     

    64,656

     

    57,155

    General and administrative

     

    8,966

     

    8,749

     

    18,213

     

    17,473

    Restructuring

     

    7,936

     

    —

     

    7,936

     

    —

    Total operating expenses

     

    67,061

     

    56,874

     

    132,694

     

    112,754

    Income from operations

     

    33,792

     

    32,101

     

    63,475

     

    53,783

    Other income, net

     

    5,903

     

    908

     

    10,742

     

    1,712

    Income before income taxes

     

    39,695

     

    33,009

     

    74,217

     

    55,495

    Provision for income taxes

     

    9,093

     

    6,710

     

    15,209

     

    6,813

    Net income

    $

    30,602

    $

    26,299

    $

    59,008

    $

    48,682

    Net income per share attributable to Class A and Class B common stockholders:

     

     

     

     

    Basic

    $

    0.16

    $

    0.14

    $

    0.30

    $

    0.25

    Diluted

    $

    0.15

    $

    0.12

    $

    0.28

    $

    0.23

    Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:

     

     

     

     

    Basic

     

    193,112

     

    193,137

     

    193,813

     

    193,042

    Diluted

     

    209,014

     

    213,949

     

    210,681

     

    214,452

    (1) Costs and expenses include stock-based compensation expense as follows (in thousands):

     

    Three Months Ended

    September 30,

    Six Months Ended

    September 30,

     

    2023

    2022

    2023

    2022

    Cost of revenue

    $

    2,278

    $

    2,392

    $

    4,739

    $

    4,514

    Research and development

     

    2,538

     

    2,862

     

    5,794

     

    5,414

    Sales and marketing

     

    2,697

     

    3,982

     

    8,692

     

    7,056

    General and administrative

     

    2,288

     

    2,117

     

    4,577

     

    3,875

    Restructuring

     

    3,646

     

    —

     

    3,646

     

    —

    Total stock-based compensation expense

    $

    13,447

    $

    11,353

    $

    27,448

    $

    20,859

    DOXIMITY, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (in thousands)

    (unaudited)

     

     

    Three Months Ended

    September 30,

    Six Months Ended

    September 30,

     

    2023

    2022

    2023

    2022

    Cash flows from operating activities

     

     

     

     

    Net income

    $

    30,602

     

    $

    26,299

     

    $

    59,008

     

    $

    48,682

     

    Adjustments to reconcile net income to net cash provided by operating activities:

     

     

     

     

    Depreciation and amortization

     

    2,604

     

     

    2,589

     

     

    5,208

     

     

    4,959

     

    Deferred income taxes

     

    —

     

     

    —

     

     

    —

     

     

    105

     

    Stock-based compensation, net of amounts capitalized

     

    13,447

     

     

    11,353

     

     

    27,448

     

     

    20,859

     

    Non-cash lease expense

     

    540

     

     

    551

     

     

    1,077

     

     

    952

     

    Amortization of premium (accretion of discount) on marketable securities, net

     

    (1,495

    )

     

    1,218

     

     

    (1,794

    )

     

    2,673

     

    Loss (gain) on sale of marketable securities

     

    (131

    )

     

    463

     

     

    142

     

     

    500

     

    Amortization of deferred contract costs

     

    2,063

     

     

    2,072

     

     

    4,730

     

     

    4,839

     

    Other

     

    137

     

     

    37

     

     

    (15

    )

     

    7

     

    Changes in operating assets and liabilities, net of effect of acquisition:

     

     

     

     

    Accounts receivable

     

    (4,388

    )

     

    (3,339

    )

     

    9,644

     

     

    2,194

     

    Prepaid expenses and other assets

     

    (13,093

    )

     

    2,405

     

     

    (10,504

    )

     

    3,651

     

    Deferred contract costs

     

    (1,238

    )

     

    (1,476

    )

     

    (2,448

    )

     

    (2,342

    )

    Accounts payable, accrued expenses and other liabilities

     

    (8,740

    )

     

    1,635

     

     

    (8,063

    )

     

    (4,474

    )

    Deferred revenue

     

    (6,831

    )

     

    (4,280

    )

     

    (13,753

    )

     

    1,872

     

    Operating lease liabilities

     

    (579

    )

     

    (13

    )

     

    (582

    )

     

    (211

    )

    Net cash provided by operating activities

     

    12,898

     

     

    39,514

     

     

    70,098

     

     

    84,266

     

    Cash flows from investing activities

     

     

     

     

    Cash paid for acquisition

     

    —

     

     

    —

     

     

    —

     

     

    (53,500

    )

    Purchases of property and equipment

     

    (41

    )

     

    (766

    )

     

    (111

    )

     

    (1,476

    )

    Internal-use software development costs

     

    (1,238

    )

     

    (1,051

    )

     

    (2,732

    )

     

    (2,466

    )

    Purchases of marketable securities

     

    (144,942

    )

     

    (82,307

    )

     

    (180,226

    )

     

    (91,177

    )

    Maturities of marketable securities

     

    96,119

     

     

    16,167

     

     

    212,768

     

     

    24,438

     

    Sales of marketable securities

     

    —

     

     

    49,434

     

     

    37,525

     

     

    64,158

     

    Net cash provided by (used in) investing activities

     

    (50,102

    )

     

    (18,523

    )

     

    67,224

     

     

    (60,023

    )

    Cash flows from financing activities

     

     

     

     

    Proceeds from issuance of common stock upon exercise of stock options and common stock warrants

     

    3,933

     

     

    2,570

     

     

    7,218

     

     

    5,584

     

    Proceeds from issuance of common stock in connection with the employee stock purchase plan

     

    1,494

     

     

    2,341

     

     

    1,494

     

     

    2,341

     

    Taxes paid related to net share settlement of equity awards

     

    (2,120

    )

     

    (1,152

    )

     

    (4,084

    )

     

    (1,261

    )

    Repurchase of common stock

     

    (164,429

    )

     

    (61,168

    )

     

    (186,184

    )

     

    (70,042

    )

    Payment of contingent consideration related to a business combination

     

    —

     

     

    —

     

     

    (5,390

    )

     

    —

     

    Net cash used in financing activities

     

    (161,122

    )

     

    (57,409

    )

     

    (186,946

    )

     

    (63,378

    )

    Net decrease in cash and cash equivalents

     

    (198,326

    )

     

    (36,418

    )

     

    (49,624

    )

     

    (39,135

    )

    Cash and cash equivalents, beginning of period

     

    306,729

     

     

    110,092

     

     

    158,027

     

     

    112,809

     

    Cash and cash equivalents, end of period

    $

    108,403

     

    $

    73,674

     

    $

    108,403

     

    $

    73,674

     

    Supplemental disclosures of cash flow information

     

     

     

     

    Cash paid for taxes, net of refunds

    $

    29,438

     

    $

    123

     

    $

    29,438

     

    $

    123

     

    Non-GAAP Financial Measures

    To supplement our consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States ("GAAP"), the Company uses the following non-GAAP measures of financial performance:

    • Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP net income, non-GAAP net income margin, and non-GAAP basic and diluted net income per common share: We exclude the effect of stock-based compensation expense, amortization of acquired intangible assets, restructuring expense, change in fair value of contingent earn-out consideration liability, and acquisition and other related expenses from non-GAAP gross profit, non-GAAP gross margin and non-GAAP operating income. Non-GAAP net income and non-GAAP net income margin are further adjusted for estimated income tax on such adjustments. We calculate income taxes on the adjustments by applying an estimated annual effective tax rate to the adjustments. Non-GAAP basic and diluted net income per common share is non-GAAP net income attributable to common stockholders divided by the weighted average number of shares. For both basic and diluted non-GAAP net income per share, the weighted average shares we use in computing non-GAAP net income per share is equal to our GAAP weighted average shares. Non-GAAP gross margin represents non-GAAP gross profit as a percentage of revenue and non-GAAP net income margin represents non-GAAP net income as a percentage of revenue.
    • Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, restructuring expense, change in fair value of contingent earn-out consideration liability, and other income, net. Net income margin represents net income as a percentage of revenue and adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.
    • Free cash flow: We calculate free cash flow as cash flow from operating activities less purchases of property and equipment and internal-use software development costs.

    We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.

    Key Business Metrics

    • Net revenue retention rate: Net revenue retention rate is calculated by taking the trailing 12-month ("TTM") subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. For the purposes of this calculation, subscription revenue excludes subscriptions for individuals and small practices and other non-recurring items. Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Our net revenue retention rate is directly tied to our revenue growth rate and thus fluctuates as that growth rate fluctuates.
    • Customers with trailing 12-month subscription revenue greater than $100,000 and $1 million: The number of customers with TTM subscription revenue greater than $100,000 and $1 million is a key indicator of the scale of our business, and is calculated by counting the number of customers that contributed more than $100,000 and $1 million in subscription revenue in the TTM period. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity, and we present our total customer count for historical periods reflecting these adjustments.

    Reconciliation of GAAP to Non-GAAP Financial Measures

    The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

     

    Three Months Ended

    September 30,

    Six Months Ended

    September 30,

     

    2023

    2022

    2023

    2022

     

    (unaudited)

     

    (in thousands, except percentages)

    Net income

    $

    30,602

     

    $

    26,299

     

    $

    59,008

     

    $

    48,682

     

    Adjusted to exclude the following:

     

     

     

     

    Acquisition and other related expenses

     

    —

     

     

    —

     

     

    —

     

     

    30

     

    Stock-based compensation

     

    9,801

     

     

    11,353

     

     

    23,802

     

     

    20,859

     

    Depreciation and amortization

     

    2,604

     

     

    2,589

     

     

    5,208

     

     

    4,959

     

    Provision for income taxes

     

    9,093

     

     

    6,710

     

     

    15,209

     

     

    6,813

     

    Restructuring expense

     

    7,936

     

     

    —

     

     

    7,936

     

     

    —

     

    Change in fair value of contingent earn-out consideration liability

     

    47

     

     

    (40

    )

     

    316

     

     

    (94

    )

    Other income, net

     

    (5,903

    )

     

    (908

    )

     

    (10,742

    )

     

    (1,712

    )

    Adjusted EBITDA

    $

    54,180

     

    $

    46,003

     

    $

    100,737

     

    $

    79,537

     

     

     

     

     

     

    Revenue

    $

    113,612

     

    $

    102,185

     

    $

    222,081

     

    $

    192,824

     

    Net income margin

     

    26.9

    %

     

    25.7

    %

     

    26.6

    %

     

    25.2

    %

    Adjusted EBITDA margin

     

    47.7

    %

     

    45.0

    %

     

    45.4

    %

     

    41.2

    %

     

    Three Months Ended

    September 30,

    Six Months Ended

    September 30,

     

    2023

    2022

    2023

    2022

     

    (unaudited)

     

    (in thousands)

    Net cash provided by operating activities

    $

    12,898

     

    $

    39,514

     

    $

    70,098

     

    $

    84,266

     

    Purchases of property and equipment

     

    (41

    )

     

    (766

    )

     

    (111

    )

     

    (1,476

    )

    Internal-use software development costs

     

    (1,238

    )

     

    (1,051

    )

     

    (2,732

    )

     

    (2,466

    )

    Free cash flow

    $

    11,619

     

    $

    37,697

     

    $

    67,255

     

    $

    80,324

     

    Other cash flow components:

     

     

     

     

    Net cash provided by (used in) investing activities

    $

    (50,102

    )

    $

    (18,523

    )

    $

    67,224

     

    $

    (60,023

    )

    Net cash used in financing activities

    $

    (161,122

    )

    $

    (57,409

    )

    $

    (186,946

    )

    $

    (63,378

    )

     

    Three Months Ended

    September 30,

    Six Months Ended

    September 30,

     

    2023

    2022

    2023

    2022

     

    (unaudited)

     

    (in thousands, except per share data and percentages)

    GAAP cost of revenue

    $

    12,759

     

    $

    13,210

     

    $

    25,912

     

    $

    26,287

     

    Adjusted to exclude the following:

     

     

     

     

    Stock-based compensation

     

    (2,278

    )

     

    (2,392

    )

     

    (4,739

    )

     

    (4,514

    )

    Amortization of acquired intangibles

     

    (137

    )

     

    (137

    )

     

    (274

    )

     

    (273

    )

    Non-GAAP cost of revenue

    $

    10,344

     

    $

    10,681

     

    $

    20,899

     

    $

    21,500

     

     

     

     

     

     

    GAAP gross profit

    $

    100,853

     

    $

    88,975

     

    $

    196,169

     

    $

    166,537

     

    Adjusted to exclude the following:

     

     

     

     

    Stock-based compensation

     

    2,278

     

     

    2,392

     

     

    4,739

     

     

    4,514

     

    Amortization of acquired intangibles

     

    137

     

     

    137

     

     

    274

     

     

    273

     

    Non-GAAP gross profit

    $

    103,268

     

    $

    91,504

     

    $

    201,182

     

    $

    171,324

     

     

     

     

     

     

    GAAP gross margin

     

    88.8

    %

     

    87.1

    %

     

    88.3

    %

     

    86.4

    %

    Non-GAAP gross margin

     

    90.9

    %

     

    89.5

    %

     

    90.6

    %

     

    88.8

    %

     

     

     

     

     

    GAAP research and development expense

    $

    19,958

     

    $

    19,104

     

    $

    41,889

     

    $

    38,126

     

    Adjusted to exclude the following:

     

     

     

     

    Stock-based compensation

     

    (2,538

    )

     

    (2,862

    )

     

    (5,794

    )

     

    (5,414

    )

    Non-GAAP research and development expense

    $

    17,420

     

    $

    16,242

     

    $

    36,095

     

    $

    32,712

     

     

     

     

     

     

    GAAP sales and marketing expense

    $

    30,201

     

    $

    29,021

     

    $

    64,656

     

    $

    57,155

     

    Adjusted to exclude the following:

     

     

     

     

    Stock-based compensation

     

    (2,697

    )

     

    (3,982

    )

     

    (8,692

    )

     

    (7,056

    )

    Amortization of acquired intangibles

     

    (1,061

    )

     

    (1,061

    )

     

    (2,122

    )

     

    (2,124

    )

    Change in fair value of contingent earn-out consideration liability

     

    (47

    )

     

    40

     

     

    (316

    )

     

    94

     

    Non-GAAP sales and marketing expense

    $

    26,396

     

    $

    24,018

     

    $

    53,526

     

    $

    48,069

     

     

     

     

     

     

    GAAP general and administrative expense

    $

    8,966

     

    $

    8,749

     

    $

    18,213

     

    $

    17,473

     

    Adjusted to exclude the following:

     

     

     

     

    Acquisition and other related expenses

     

    —

     

     

    —

     

     

    —

     

     

    (30

    )

    Stock-based compensation

     

    (2,288

    )

     

    (2,117

    )

     

    (4,577

    )

     

    (3,875

    )

    Non-GAAP general and administrative expense

    $

    6,678

     

    $

    6,632

     

    $

    13,636

     

    $

    13,568

     

     

     

     

     

     

    GAAP operating expense

    $

    67,061

     

    $

    56,874

     

    $

    132,694

     

    $

    112,754

     

    Adjusted to exclude the following:

     

     

     

     

    Acquisition and other related expenses

     

    —

     

     

    —

     

     

    —

     

     

    (30

    )

    Stock-based compensation

     

    (7,523

    )

     

    (8,961

    )

     

    (19,063

    )

     

    (16,345

    )

    Amortization of acquired intangibles

     

    (1,061

    )

     

    (1,061

    )

     

    (2,122

    )

     

    (2,124

    )

    Change in fair value of contingent earn-out consideration liability

     

    (47

    )

     

    40

     

     

    (316

    )

     

    94

     

    Restructuring

     

    (7,936

    )

     

    —

     

     

    (7,936

    )

     

    —

     

    Non-GAAP operating expense

    $

    50,494

     

    $

    46,892

     

    $

    103,257

     

    $

    94,349

     

     

     

     

     

     

    GAAP operating income

    $

    33,792

     

    $

    32,101

     

    $

    63,475

     

    $

    53,783

     

    Adjusted to exclude the following:

     

     

     

     

    Acquisition and other related expenses

     

    —

     

     

    —

     

     

    —

     

     

    30

     

    Stock-based compensation

     

    9,801

     

     

    11,353

     

     

    23,802

     

     

    20,859

     

    Amortization of acquired intangibles

     

    1,198

     

     

    1,198

     

     

    2,396

     

     

    2,397

     

    Change in fair value of contingent earn-out consideration liability

     

    47

     

     

    (40

    )

     

    316

     

     

    (94

    )

    Restructuring

     

    7,936

     

     

    —

     

     

    7,936

     

     

    —

     

    Non-GAAP operating income

    $

    52,774

     

    $

    44,612

     

    $

    97,925

     

    $

    76,975

     

     

     

     

     

     

    GAAP net income

    $

    30,602

     

    $

    26,299

     

    $

    59,008

     

    $

    48,682

     

    Adjusted to exclude the following:

     

     

     

     

    Acquisition and other related expenses

     

    —

     

     

    —

     

     

    —

     

     

    30

     

    Stock-based compensation

     

    9,801

     

     

    11,353

     

     

    23,802

     

     

    20,859

     

    Amortization of acquired intangibles

     

    1,198

     

     

    1,198

     

     

    2,396

     

     

    2,397

     

    Change in fair value of contingent earn-out consideration liability

     

    47

     

     

    (40

    )

     

    316

     

     

    (94

    )

    Restructuring

     

    7,936

     

     

    —

     

     

    7,936

     

     

    —

     

    Income tax effect of non-GAAP adjustments (1)

     

    (3,986

    )

     

    (2,627

    )

     

    (7,235

    )

     

    (4,870

    )

    Non-GAAP net income

    $

    45,598

     

    $

    36,183

     

    $

    86,223

     

    $

    67,004

     

    Non-GAAP net income margin

     

    40.1

    %

     

    35.4

    %

     

    38.8

    %

     

    34.7

    %

     

     

     

     

     

    Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:

     

     

     

     

    Basic

     

    193,112

     

     

    193,137

     

     

    193,813

     

     

    193,042

     

    Diluted

     

    209,014

     

     

    213,949

     

     

    210,681

     

     

    214,452

     

     

     

     

     

     

    Non-GAAP net income per share attributable to Class A and Class B stockholders:

     

     

     

     

    Basic

    $

    0.24

     

    $

    0.19

     

    $

    0.44

     

    $

    0.35

     

    Diluted

    $

    0.22

     

    $

    0.17

     

    $

    0.41

     

    $

    0.31

     

    (1)

    For the three and six months ended September 30, 2023 and 2022, management used an estimated annual effective non-GAAP tax rate of 21.0%.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231109485823/en/

    Get the next $DOCS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DOCS

    DatePrice TargetRatingAnalyst
    2/9/2026$34.00Hold → Buy
    Canaccord Genuity
    2/6/2026$40.00Underweight → Neutral
    Analyst
    1/20/2026$55.00Equal Weight → Overweight
    Wells Fargo
    1/9/2026$59.00Outperform
    RBC Capital Mkts
    1/8/2026Hold → Buy
    Truist
    12/15/2025$65.00Equal-Weight → Overweight
    Morgan Stanley
    12/9/2025$63.00Overweight
    Barclays
    11/21/2025$65.00Outperform → Strong Buy
    Raymond James
    More analyst ratings

    $DOCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Doximity Ranked #1 Best in KLAS Telehealth Video Platform for Fifth Consecutive Year

    Doximity Dialer earns A-level ratings in all categories Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, announced today that Doximity Dialer has been named the #1 Telehealth Video Conferencing Platform in the 2026 Best in KLAS Report. This is the fifth consecutive year that Doximity has earned the top spot, underscoring its position as a trusted, long-term partner for physicians and health systems. In addition to securing the #1 spot, Doximity received A-level ratings in all categories, including A+ ratings for culture, loyalty and value. These results are based on live interviews with health system leaders and their staff, reflecting high satisf

    2/5/26 4:05:00 PM ET
    $DOCS
    EDP Services
    Technology

    Doximity to Release Fiscal 2026 Third Quarter Results on February 5, 2026

    Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal third quarter ended December 31, 2025 after market close on February 5, 2026. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members inclu

    1/15/26 4:01:00 PM ET
    $DOCS
    EDP Services
    Technology

    Healthcare AI Exits Pilot Phase, Enters Production Deployment

    VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Healthcare organizations are setting the pace for enterprise AI adoption as operational automation moves from experimentation to production scale across hospital systems[1]. The shift reflects a fundamental change in how healthcare leaders view AI technology, with deployment projected to expand the global healthcare AI market from $17.2 billion in 2025 to $77.2 billion by 2035[2]. Five publicly traded companies are positioned at the intersection of this operational transformation, delivering infrastructure that turns AI capabilities into measurable workflow improvements and financial returns

    12/12/25 9:59:27 AM ET
    $CERT
    $CTSH
    $DOCS
    Computer Software: Prepackaged Software
    Technology
    EDP Services
    Medical Specialities

    $DOCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Doximity upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded Doximity from Hold to Buy and set a new price target of $34.00

    2/9/26 6:58:22 AM ET
    $DOCS
    EDP Services
    Technology

    Doximity upgraded by Analyst with a new price target

    Analyst upgraded Doximity from Underweight to Neutral and set a new price target of $40.00

    2/6/26 8:05:27 AM ET
    $DOCS
    EDP Services
    Technology

    Doximity upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Doximity from Equal Weight to Overweight and set a new price target of $55.00

    1/20/26 8:43:16 AM ET
    $DOCS
    EDP Services
    Technology

    $DOCS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Interim PFO and PAO Sitaram Siddharth covered exercise/tax liability with 946 shares and was granted 10,376 shares, increasing direct ownership by 14% to 78,733 units (SEC Form 4)

    4 - Doximity, Inc. (0001516513) (Issuer)

    2/18/26 9:54:35 PM ET
    $DOCS
    EDP Services
    Technology

    Chief Financial Officer Bryson Anna was granted 152,258 shares and covered exercise/tax liability with 11,381 shares, increasing direct ownership by 39% to 505,549 units (SEC Form 4)

    4 - Doximity, Inc. (0001516513) (Issuer)

    2/18/26 9:53:26 PM ET
    $DOCS
    EDP Services
    Technology

    Chief Executive Officer Tangney Jeffrey covered exercise/tax liability with 8,243 shares, decreasing direct ownership by 0.37% to 2,232,810 units (SEC Form 4)

    4 - Doximity, Inc. (0001516513) (Issuer)

    2/18/26 9:48:04 PM ET
    $DOCS
    EDP Services
    Technology

    $DOCS
    SEC Filings

    View All

    SEC Form 10-Q filed by Doximity Inc.

    10-Q - Doximity, Inc. (0001516513) (Filer)

    2/5/26 4:09:11 PM ET
    $DOCS
    EDP Services
    Technology

    Doximity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - Doximity, Inc. (0001516513) (Filer)

    2/5/26 4:03:25 PM ET
    $DOCS
    EDP Services
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Doximity Inc.

    SCHEDULE 13G/A - Doximity, Inc. (0001516513) (Subject)

    2/5/26 1:23:13 PM ET
    $DOCS
    EDP Services
    Technology

    $DOCS
    Financials

    Live finance-specific insights

    View All

    Doximity to Release Fiscal 2026 Third Quarter Results on February 5, 2026

    Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal third quarter ended December 31, 2025 after market close on February 5, 2026. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members inclu

    1/15/26 4:01:00 PM ET
    $DOCS
    EDP Services
    Technology

    Doximity to Release Fiscal 2026 Second Quarter Results on November 6, 2025

    Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal second quarter ended September 30, 2025 after market close on November 6, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members inc

    10/16/25 4:01:00 PM ET
    $DOCS
    EDP Services
    Technology

    Doximity Acquires Pathway, a Leader in AI Clinical Reference

    $63M acquisition brings physician AI team and datasets to Doximity's AI suite Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced that it has acquired Pathway Medical Inc., a Montreal-based startup specializing in medical AI and evidence-based clinical reference. Physicians make up half of Pathway's team. Over the past seven years, they've assembled one of the largest structured datasets in medicine—purpose-built for AI—spanning nearly every guideline, drug, and landmark trial across all major specialties. Pathway's model outperforms others in clinical accuracy, recently scoring a record 96% on the U.S. Medical Licensing Examination (

    8/7/25 4:02:00 PM ET
    $DOCS
    EDP Services
    Technology

    $DOCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Doximity Inc.

    SC 13G/A - Doximity, Inc. (0001516513) (Subject)

    11/14/24 5:22:01 PM ET
    $DOCS
    EDP Services
    Technology

    SEC Form SC 13G filed by Doximity Inc.

    SC 13G - Doximity, Inc. (0001516513) (Subject)

    11/14/24 11:42:53 AM ET
    $DOCS
    EDP Services
    Technology

    SEC Form SC 13G filed by Doximity Inc.

    SC 13G - Doximity, Inc. (0001516513) (Subject)

    11/12/24 9:55:17 AM ET
    $DOCS
    EDP Services
    Technology

    $DOCS
    Leadership Updates

    Live Leadership Updates

    View All

    Parspec Raises $20 Million Series A to Modernize the Construction Supply Chain with AI

    SAN MATEO, Calif., July 8, 2025 /PRNewswire/ -- Parspec, an AI-native software platform that enables wholesale distributors and sales agents to efficiently bid and supply construction products, today announced it has raised $20 million in Series A funding. The round was led by Threshold Ventures (formerly DFJ), with participation from existing venture investors including Innovation Endeavors, Building Ventures, Heartland Ventures, and Hometeam Ventures. Parspec Raises $20 Million Series A to Modernize the Construction Supply Chain with AIThe global construction industry repres

    7/8/25 9:30:00 AM ET
    $BOX
    $DOCS
    $RELY
    Computer Software: Prepackaged Software
    Technology
    EDP Services
    Real Estate

    Mendaera Closes $73M Series B Financing to Scale Robotics and AI Across Mainstream Medical Procedures

    With its first-of-its-kind platform, Mendaera is pioneering a new category in medical robotics Mendaera, Inc., a Silicon Valley-based healthcare technology company developing a handheld robotic interventional platform, announced today the close of $73 million in Series B funding led by Threshold Ventures, with participation from investors including Lux Capital, PFM Health Sciences, and Fred Moll (founder of Intuitive Surgical and Auris Health). The financing will further Mendaera's efforts to scale robotics and AI across mainstream medical procedures. The healthcare system is facing an increasing supply and demand crisis, where the ability to consistently deliver high-quality care to pati

    9/26/24 6:05:00 AM ET
    $DOCS
    $RELY
    $LVGO
    EDP Services
    Technology
    Real Estate
    Computer Software: Programming, Data Processing

    Doximity Appoints Phoebe Yang to Its Board of Directors

    Experienced director and executive brings health system and cloud expertise SAN FRANCISCO, Aug. 4, 2022 /PRNewswire/ -- Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced the appointment of Phoebe L. Yang to its Board of Directors. Ms. Yang has been General Manager at Amazon Web Services, Healthcare, and a member of the board of directors for CommonSpirit Health, one of the largest U.S. health systems. Ms. Yang is a long-time member of the Council on Foreign Relations, and has served as an appointee in two Presidential Administrations. In 2021, she was named one of Modern Healthcare's Top 100 Most Influential People in Healthcare and one

    8/4/22 4:02:00 PM ET
    $DOCS
    EDP Services
    Technology